Split-dose cisplatin and vinorelbine as adjuvant chemotherapy for completely resected non-small cell lung cancer

Fumihiko Hirai, Takashi Seto, Mototsugu Shimokawa, Eiko Inamasu, Ryo Toyozawa, Gouji Toyokawa, Tsukihisa Yoshida, Yoshimasa Shiraishi, Tomoyoshi Takenaka, Masafumi Yamaguchi, Mitsuhiro Takenoyama, Yukito Ichinose

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Aim: The aim of the present study was to evaluate the feasibility of, and compliance with a regimen using split-dose cisplatin and vinorelbine (split-CV) as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer (NSCLC). Patiets and Methods: The treatment schedule included cisplatin at 40 mg/m2 and vinorelbine at 25 mg/m2 administered intravenously on days 1 and 8, every three weeks for four cycles. Results: This study included 22 patients (male/female; 12/10) with a median age of 67 (range 50-76) years; 10 had clinical stage II and 12 stage III; 21 had ECOG 0 and 1 patient ECOG 1; 15 patients had adenocarcinoma, 5 squamous cell and 2 adenosquamous carcinoma; 18 patients had undergone lobectomy, 3 pneumonectomy and 1 segmentectomy. Seventeen out of 22 patients (77%) received the planned 4 cycles. The main adverse events were grade 3/4 neutropenia (76%) and anemia (12%). The average total doses of cisplatin and vinorelbine were 285 mg/m2 and 177 mg/m2, respectively. Conclusion: The split-CV regimen is well-tolerated as adjuvant chemotherapy for completely resected NSCLC.

Original languageEnglish
Pages (from-to)927-932
Number of pages6
JournalAnticancer research
Volume34
Issue number2
Publication statusPublished - Feb 1 2014

Fingerprint

Adjuvant Chemotherapy
Non-Small Cell Lung Carcinoma
Cisplatin
Adenosquamous Carcinoma
Segmental Mastectomy
Pneumonectomy
Neutropenia
vinorelbine
Anemia
Appointments and Schedules
Adenocarcinoma
Epithelial Cells

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Hirai, F., Seto, T., Shimokawa, M., Inamasu, E., Toyozawa, R., Toyokawa, G., ... Ichinose, Y. (2014). Split-dose cisplatin and vinorelbine as adjuvant chemotherapy for completely resected non-small cell lung cancer. Anticancer research, 34(2), 927-932.

Split-dose cisplatin and vinorelbine as adjuvant chemotherapy for completely resected non-small cell lung cancer. / Hirai, Fumihiko; Seto, Takashi; Shimokawa, Mototsugu; Inamasu, Eiko; Toyozawa, Ryo; Toyokawa, Gouji; Yoshida, Tsukihisa; Shiraishi, Yoshimasa; Takenaka, Tomoyoshi; Yamaguchi, Masafumi; Takenoyama, Mitsuhiro; Ichinose, Yukito.

In: Anticancer research, Vol. 34, No. 2, 01.02.2014, p. 927-932.

Research output: Contribution to journalArticle

Hirai, F, Seto, T, Shimokawa, M, Inamasu, E, Toyozawa, R, Toyokawa, G, Yoshida, T, Shiraishi, Y, Takenaka, T, Yamaguchi, M, Takenoyama, M & Ichinose, Y 2014, 'Split-dose cisplatin and vinorelbine as adjuvant chemotherapy for completely resected non-small cell lung cancer', Anticancer research, vol. 34, no. 2, pp. 927-932.
Hirai F, Seto T, Shimokawa M, Inamasu E, Toyozawa R, Toyokawa G et al. Split-dose cisplatin and vinorelbine as adjuvant chemotherapy for completely resected non-small cell lung cancer. Anticancer research. 2014 Feb 1;34(2):927-932.
Hirai, Fumihiko ; Seto, Takashi ; Shimokawa, Mototsugu ; Inamasu, Eiko ; Toyozawa, Ryo ; Toyokawa, Gouji ; Yoshida, Tsukihisa ; Shiraishi, Yoshimasa ; Takenaka, Tomoyoshi ; Yamaguchi, Masafumi ; Takenoyama, Mitsuhiro ; Ichinose, Yukito. / Split-dose cisplatin and vinorelbine as adjuvant chemotherapy for completely resected non-small cell lung cancer. In: Anticancer research. 2014 ; Vol. 34, No. 2. pp. 927-932.
@article{aca4b535265a41f0a0334799b48b73df,
title = "Split-dose cisplatin and vinorelbine as adjuvant chemotherapy for completely resected non-small cell lung cancer",
abstract = "Aim: The aim of the present study was to evaluate the feasibility of, and compliance with a regimen using split-dose cisplatin and vinorelbine (split-CV) as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer (NSCLC). Patiets and Methods: The treatment schedule included cisplatin at 40 mg/m2 and vinorelbine at 25 mg/m2 administered intravenously on days 1 and 8, every three weeks for four cycles. Results: This study included 22 patients (male/female; 12/10) with a median age of 67 (range 50-76) years; 10 had clinical stage II and 12 stage III; 21 had ECOG 0 and 1 patient ECOG 1; 15 patients had adenocarcinoma, 5 squamous cell and 2 adenosquamous carcinoma; 18 patients had undergone lobectomy, 3 pneumonectomy and 1 segmentectomy. Seventeen out of 22 patients (77{\%}) received the planned 4 cycles. The main adverse events were grade 3/4 neutropenia (76{\%}) and anemia (12{\%}). The average total doses of cisplatin and vinorelbine were 285 mg/m2 and 177 mg/m2, respectively. Conclusion: The split-CV regimen is well-tolerated as adjuvant chemotherapy for completely resected NSCLC.",
author = "Fumihiko Hirai and Takashi Seto and Mototsugu Shimokawa and Eiko Inamasu and Ryo Toyozawa and Gouji Toyokawa and Tsukihisa Yoshida and Yoshimasa Shiraishi and Tomoyoshi Takenaka and Masafumi Yamaguchi and Mitsuhiro Takenoyama and Yukito Ichinose",
year = "2014",
month = "2",
day = "1",
language = "English",
volume = "34",
pages = "927--932",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "2",

}

TY - JOUR

T1 - Split-dose cisplatin and vinorelbine as adjuvant chemotherapy for completely resected non-small cell lung cancer

AU - Hirai, Fumihiko

AU - Seto, Takashi

AU - Shimokawa, Mototsugu

AU - Inamasu, Eiko

AU - Toyozawa, Ryo

AU - Toyokawa, Gouji

AU - Yoshida, Tsukihisa

AU - Shiraishi, Yoshimasa

AU - Takenaka, Tomoyoshi

AU - Yamaguchi, Masafumi

AU - Takenoyama, Mitsuhiro

AU - Ichinose, Yukito

PY - 2014/2/1

Y1 - 2014/2/1

N2 - Aim: The aim of the present study was to evaluate the feasibility of, and compliance with a regimen using split-dose cisplatin and vinorelbine (split-CV) as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer (NSCLC). Patiets and Methods: The treatment schedule included cisplatin at 40 mg/m2 and vinorelbine at 25 mg/m2 administered intravenously on days 1 and 8, every three weeks for four cycles. Results: This study included 22 patients (male/female; 12/10) with a median age of 67 (range 50-76) years; 10 had clinical stage II and 12 stage III; 21 had ECOG 0 and 1 patient ECOG 1; 15 patients had adenocarcinoma, 5 squamous cell and 2 adenosquamous carcinoma; 18 patients had undergone lobectomy, 3 pneumonectomy and 1 segmentectomy. Seventeen out of 22 patients (77%) received the planned 4 cycles. The main adverse events were grade 3/4 neutropenia (76%) and anemia (12%). The average total doses of cisplatin and vinorelbine were 285 mg/m2 and 177 mg/m2, respectively. Conclusion: The split-CV regimen is well-tolerated as adjuvant chemotherapy for completely resected NSCLC.

AB - Aim: The aim of the present study was to evaluate the feasibility of, and compliance with a regimen using split-dose cisplatin and vinorelbine (split-CV) as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer (NSCLC). Patiets and Methods: The treatment schedule included cisplatin at 40 mg/m2 and vinorelbine at 25 mg/m2 administered intravenously on days 1 and 8, every three weeks for four cycles. Results: This study included 22 patients (male/female; 12/10) with a median age of 67 (range 50-76) years; 10 had clinical stage II and 12 stage III; 21 had ECOG 0 and 1 patient ECOG 1; 15 patients had adenocarcinoma, 5 squamous cell and 2 adenosquamous carcinoma; 18 patients had undergone lobectomy, 3 pneumonectomy and 1 segmentectomy. Seventeen out of 22 patients (77%) received the planned 4 cycles. The main adverse events were grade 3/4 neutropenia (76%) and anemia (12%). The average total doses of cisplatin and vinorelbine were 285 mg/m2 and 177 mg/m2, respectively. Conclusion: The split-CV regimen is well-tolerated as adjuvant chemotherapy for completely resected NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=84897036148&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897036148&partnerID=8YFLogxK

M3 - Article

C2 - 24511034

AN - SCOPUS:84897036148

VL - 34

SP - 927

EP - 932

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 2

ER -